Rebecca Berhanu to Tuberculosis, Multidrug-Resistant
This is a "connection" page, showing publications Rebecca Berhanu has written about Tuberculosis, Multidrug-Resistant.
Connection Strength
2,121
-
Can patients afford the cost of treatment for multidrug-resistant tuberculosis in Ethiopia? Int J Tuberc Lung Dis. 2018 08 01; 22(8):358-362.
Score: 0,501
-
Treatment and pregnancy outcomes of pregnant women exposed to second-line anti-tuberculosis drugs in South Africa. BMC Pregnancy Childbirth. 2021 Jun 28; 21(1):453.
Score: 0,153
-
Managing multidrug-resistant tuberculosis in South Africa: a budget impact analysis. Int J Tuberc Lung Dis. 2020 04 01; 24(4):376-382.
Score: 0,141
-
Data quality of drug-resistant tuberculosis and antiretroviral therapy electronic registers in South Africa. BMC Public Health. 2019 Dec 05; 19(1):1638.
Score: 0,137
-
Cost outcome analysis of decentralized care for drug-resistant tuberculosis in Johannesburg, South Africa. PLoS One. 2019; 14(6):e0217820.
Score: 0,133
-
The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa. Health Qual Life Outcomes. 2019 May 31; 17(1):94.
Score: 0,133
-
Discordant rifampicin susceptibility results are associated with Xpert® MTB/RIF probe B and probe binding delay. Int J Tuberc Lung Dis. 2019 03 01; 23(3):358-362.
Score: 0,130
-
Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa. BMC Health Serv Res. 2018 Dec 17; 18(1):973.
Score: 0,129
-
Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa. Int J Tuberc Lung Dis. 2018 04 01; 22(4):393-398.
Score: 0,122
-
Persistently high early mortality despite rapid diagnostics for drug-resistant tuberculosis cases in South Africa. Int J Tuberc Lung Dis. 2017 10 01; 21(10):1106-1111.
Score: 0,118
-
Treatment initiation among persons diagnosed with drug resistant tuberculosis in Johannesburg, South Africa. PLoS One. 2017; 12(7):e0181238.
Score: 0,117
-
Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis. J Antimicrob Chemother. 2017 07 01; 72(7):1871-1879.
Score: 0,116
-
A call to action: Addressing the reproductive health needs of women with drug-resistant tuberculosis. S Afr Med J. 2016 Mar 17; 106(4):30-1.
Score: 0,106
-
High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa. PLoS One. 2018; 13(10):e0205463.
Score: 0,032
-
Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study. BMC Infect Dis. 2016 Oct 21; 16(1):593.
Score: 0,028
-
Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: a cohort analysis of the national case register. Int J Infect Dis. 2015 Oct; 39:89-94.
Score: 0,026